Leo told several shareholders who visited the company that they have enough funds to run all the planned trials in the next 12 months. Nasdaq also wants to see that (going concerns) in the 10-K. It sounds to me like CTIX doesn’t need much dilution in the short term.
If B-OM works, then we don’t need to worry about dilutions if Leo can find a partner. IMO he’s trying to partner the whole defensin-mimetics platform instead of B-ABSSSI and B-OM separately. So the deal could be huge and it’s definitely worth the wait.
With an 88% strong sell CTIX rating, and down 60% YTD from the Ben Sharvy 4.20's expresses the trend and the death cross and the retail only market sentiment well enough. Should I buy again at a 100% sell rating or add to a losing position which I don't have? Not..........
News 
Market Data 
Discover 
